Baranowska Boguslawa, Kochanowski Jan
Department of Neurology, Medical University of Warsaw, Second Faculty of Medicine, Bielanski Hospital, Warsaw, Poland.
Neuro Endocrinol Lett. 2019 Dec;40(5):207-214.
Copeptin, arginine vasopressin (AVP)-associated 39 aminoacid glycopeptide, is a C-terminal part of pro-AVP. AVP acts through V1a, V1b, and V2 receptors. The effect on V1a receptors is connected with arterial vasoconstriction, on V2 with antidiuretic action, and on V1b with the secretion of ACTH, insulin, glucagon. Copeptin is found in the circulation in equimolar amounts with AVP. It is a very stable peptide and easy to estimate. Copeptin is a good diagnostic marker in many disorders in which vasopressinergic dysfunction plays a role in pathogenesis such as a polyuria-polydipsia syndrome, neurological disease (ischemic stroke, nontraumatic, intracerebral hemorrhage, aneurysmal subarachnoid hemorrhage and neurodegenerative disease (multiple sclerosis). Copeptin is a diagnostic and prognostic marker in cardiovascular diseases like heart failure (HF) and acute myocardial infarct (AMI). Copeptin is a sensitive diagnostic marker in the early stage of AMI especially in patients with non-ST segment elevation and post AMI complications. Copeptin is also an important diagnostic and prognostic marker in metabolic diseases (diabetes mellitus, metabolic syndrome, insulin resistance), connected with some neurological and cardiovascular diseases. In the future, these findings may have also therapeutic applications in conditions where the AVP receptor antagonist therapy is appropriate.
copeptin，一种与精氨酸加压素（AVP）相关的39个氨基酸的糖肽，是前体AVP的C末端部分。AVP通过V1a、V1b和V2受体发挥作用。对V1a受体的作用与动脉血管收缩有关，对V2受体的作用与抗利尿作用有关，对V1b受体的作用与促肾上腺皮质激素、胰岛素、胰高血糖素的分泌有关。copeptin在循环中与AVP以等摩尔量存在。它是一种非常稳定的肽，易于检测。copeptin是许多疾病中的良好诊断标志物，在这些疾病中，血管加压素能功能障碍在发病机制中起作用，如多尿-多饮综合征、神经系统疾病（缺血性中风、非创伤性脑出血、动脉瘤性蛛网膜下腔出血）和神经退行性疾病（多发性硬化症）。copeptin是心血管疾病如心力衰竭（HF）和急性心肌梗死（AMI）中的诊断和预后标志物。copeptin是AMI早期尤其是非ST段抬高患者和AMI后并发症患者的敏感诊断标志物。copeptin也是代谢性疾病（糖尿病、代谢综合征、胰岛素抵抗）中的重要诊断和预后标志物，这些疾病与一些神经和心血管疾病有关。未来，这些发现可能在AVP受体拮抗剂治疗合适的情况下也有治疗应用。
